Advertisement

Topics

Shire Limited Company Profile

14:56 EDT 19th September 2017 | BioPortfolio


News Articles [285 Associated News Articles listed on BioPortfolio]

Shire plc: Shire plc Director and Senior Management Changes

Shire plc Director and Senior Management Changes August 21, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) ("Shire" or the "Company"), announces changes to its Executive Committee, as it progresses its...

Shire Pharmaceuticals Group: SHIRE TO PRESENT NEW DATA AT ISTH 2017 TO ADVANCE THE STANDARD OF CARE IN HEMOPHILIA

More than 35 presentations and sessions showcase Shire's gene therapy pipeline and leading factor portfolio Zug, Switzerland - June 23, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), a leading biotech...

Shire plc: Director and Senior Management Changes

Shire plc Director and Senior Management ChangesAugust 21, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) ('Shire' or the 'Company'), announces changes to its Executive Committee, as it progresses its ...

Shire plc: Half-yearly report

Half-yearly ReportAugust 4, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), ('Shire' / the 'Group') in accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, is p...

Shire plans filing for HAE drug after phase 3 success

Shire plans to file its lanadelumab for the rare genetic disorder, hereditary angioedema (HAE), on the back of new phase 3 data showing the drug reduces monthly swelling attacks when taken as a preven...

Shire: Innovative Therapies for Rare Diseases

SOURCE: Shire Pharmaceuticals DESCRIPTION:Shire is the global leader in serving patients with rare diseases. We strive to develop innovative therapies across a core of rare disease areas, supplemented...

Hon tar över Shires Nordenavdelning

Shire värvar Anna-Lena Engwall som vd för Shire i Norden och Baltikum.

Shire beats earnings expectations, ups guidance

Ireland-headquartered Shire’s shares were up 4.1% at £43.73 with the first 80 minutes of trading this…

PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

Shire divests mRNA platform to RaNa.

Investigations on therapeutic glucocerebrosidases through paired detection with fluorescent activity-based probes.

Deficiency of glucocerebrosidase (GBA) causes Gaucher disease (GD). In the common non-neuronopathic GD type I variant, glucosylceramide accumulates primarily in the lysosomes of visceral macrophages. ...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Fed Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg

The objective of this study was to investigate the bioequivalence of Mylan's anagrelide HCl 1 mg capsules to Shire US's Agrylin® 1 mg capsules following a single, oral 1 mg (1 x 1 mg) dos...

Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg

The objective of this study was to investigate the bioequivalence of Mylan's anagrelide HCl 1 mg capsules to Shire US's Agrylin® 1 mg capsules following a single, oral 1 mg (1 x 1 mg) dos...

Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

The primary purpose of this study is to test the efficacy of Lisdexamfetamine in Adults With Attention Deficit Hyperactivity Disorder (ADHD) and Sluggish Cognitive Tempo (SCT). This is a p...

Companies [98 Associated Companies listed on BioPortfolio]

Shire Ltd.

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit a...

Shire Ltd

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit a...

Shire plc

Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is focused on developing specialty CNS products designed to address unmet medical needs. The company’s portfolio is well diversified wit...

Shire

Founded in 1986, Shire plc is a global specialty pharmaceutical company with revenues for the full year 2005 of $1,599.3 million and an operating income of $(354.1) million. The growth rates for reven...

More Information about "Shire Limited" on BioPortfolio

We have published hundreds of Shire Limited news stories on BioPortfolio along with dozens of Shire Limited Clinical Trials and PubMed Articles about Shire Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Shire Limited Companies in our database. You can also find out about relevant Shire Limited Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record